newsfilter
← Latest News
Business Wire·

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

  • Glaukos Corporation will present its technologies at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., held April 10-13, 2026.
  • The company will exhibit onsite at booth #407.
  • Glaukos is sponsoring an educational symposium with ASCRS and EyeWorld on Friday, April 10, 2026, from 12:00-1:00 p.m. ET to introduce Epioxa™, the first FDA-approved, epithelium-on, oxygen-enriched corneal cross-linking treatment.
  • Key presentations include 12-month outcomes for standalone third-generation Trabecular Micro-Bypass Stents, design reviews for a novel Keratoconus screening device, 12-month outcomes for the Travoprost Intracameral Implant, real-world outcomes combining stents with implants or cataract surgery, and 3-month safety and efficacy data for the Travoprost Intracameral Implant 75 mcg.
  • On-demand posters will cover persistence of epithelium-on cross-linking effects, 3-month outcomes of the Travoprost Implant combined with the Trabecular Micro-Bypass System, 1-month outcomes of stents plus implants, 3-month outcomes of the second-generation Travoprost Implant, and 2-year outcomes after stent placement with phacoemulsification.
  • Epioxa™ HD and Epioxa are riboflavin ophthalmic solutions indicated for epithelium-on corneal collagen cross-linking in adults and pediatric patients aged 13+ with keratoconus, used with the O2n™ System and Boost Goggles®.
  • iDose® TR is a long-duration, intracameral travoprost implant designed to deliver 24/7 glaucoma therapy for open-angle glaucoma or ocular hypertension.
  • The iStent infinite® Trabecular Micro-Bypass System is an implantable device indicated for reducing intraocular pressure in adult patients with primary open-angle glaucoma who have failed previous treatments.
  • The press release includes standard forward-looking statement disclaimers regarding regulatory approvals, commercialization, reimbursement, and product efficacy.